Alan Tan, MD

Director of GU Medical Oncology and Assistant Professor at RUSH Medical College

Articles by Alan Tan, MD

Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their excitement for the road ahead in kidney cancer.
View More
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
Alan Tan, MDUromigos Live 2023 | November 8, 2023
Dr. Alan Tan compares the PSMAfore and VISION studies and comments on the controversy regarding OS benefit in the former.
Alan Tan, MDProstate Cancer | September 13, 2023
The FDA may allow the temporary use of drugs from overseas to alleviate the ongoing cisplatin and carboplatin shortages.